|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||35.17 - 35.49|
|52 Week Range||30.51 - 36.78|
|PE Ratio (TTM)||25.87|
|Forward Dividend & Yield||1.28 (3.60%)|
|1y Target Est||N/A|
Open enrollment is going strong for the Affordable Care Act. Almost 1.5M people have signed up for Obamacare during the first two weeks of open enrollment. That's up a whopping 46% compared to the same time last year. Yahoo Finance’s Alexis Christoforous and Myles Udland figure out what’s behind the sharp increase.
Senate Republicans have wanted to kill the Obamacare individual mandate for a long time and now they're looking to do it as part of their tax reform proposal. Senate Majority Leader Mitch McConnell says the GOP tax plan will now include a provision to repeal the Obamacare mandate, which requires everyone to have health insurance. Yahoo Finance’s Alexis Christoforous and Rick Newman breakdown what this means for Americans.
A Nevada prisons official said Friday the state is refusing pharmaceutical company Pfizer's demand to return a drug it manufactured and not use it in a planned lethal injection execution.
LAS VEGAS (AP) — For Nevada's first execution in more than a decade, state officials are turning to a never-before-tried combination of drugs, including a powerful painkiller that is fueling much of the nation's opioid epidemic and a paralyzing drug that could mask any signs of trouble.
The Latest on a pharmaceutical company's demand that states not use drugs it made for lethal injection executions (all times local): 5:30 p.m. An official says Nevada doesn't plan to return one of the ...
Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.
Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold."
Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. Early this week, Purkiss made a point of saying sales of Ibrance is being underestimated, suggesting that rather than achieving just a little less than $7 billion in revenue in 2023, it could actually produce nearly $13-billion worth of business that year as its approved uses were expanded and caregivers saw its efficacy.
This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.
In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.
Sumatriptan is the only injectable triptan approved for use in the US. The product achieved a market share of 26.0% in 2Q17, up from 21.0% in 1Q17.
Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service. Both are oral drugs, given in concert with hormonal therapies, that inhibit two proteins called CDK 4 and 6. A third CDK 4/6 drug from Eli Lilly is also licensed in the United States but not yet in Europe.
New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Generic drugmakers have been taken to the woodshed, with Teva Pharmaceutical Industries Ltd (NYSE:TEVA) down 67% year-to-date and Mallinckrodt PLC (NYSE:MNK) off 56%.
Let’s talk about the popular Pfizer Inc (NYSE:PFE). The company’s shares received a lot of attention from a substantial price movement on the NYSE in the over the last fewRead More...
Categories: Yahoo FinanceGet free summary analysis Pfizer Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Pfizer Inc. – Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Mylan N.V., ... Read more (Read more...)
In 3Q17, Novartis's (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).
Rather, it’s a way to determine if they’re looking to hit a home run or a comfortable single. Pfizer Inc. (NYSE:PFE) and PFE stock is a good example of this. Depending on what you’re looking to accomplish by investing in Pfizer, I’ll have a better idea whether you should buy, sell or hold. If you had owned Pfizer since the market bottom in March 2009, you’ve done astronomically well on your investment.
The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global
A dangerous shortage of saline bags, years in the making, has gotten worse after Hurricane Maria knocked out factories in Puerto Rico.